Systemic Immune-Inflammatory Index as a Predictor of Lymph Node Metastasis in Endometrial Cancer

References

• Lee J, Kong T, Paek J, Chang S, Ryu H. Predicting model of lymph node metastasis using preoperative tumor grade, transvaginal ultrasound, and serum CA-125 level in patients with endometrial cancer. Int J Gynecol Cancer. 2016;26(9):1630–1635. doi:10.1097/IGC.0000000000000820
   PubMed Web of Science ®Google Scholar
• Karalok A, Turan T, Basaran D, et al. Lymph node metastasis in patients with endometrioid endometrial cancer: overtreatment is the main issue. Int J Gynecol Cancer. 2017;27(4):748–753. doi:10.1097/IGC.0000000000000937
   PubMed Web of Science ®Google Scholar
• Sari M, Yalcin İ, Sahin H, Meydanli M, Gungor T. Risk factors for paraaortic lymph node metastasis in endometrial cancer. Int J Clin Oncol. 2017;22(5):937–944. doi:10.1007/s10147-017-1139-5
   PubMed Web of Science ®Google Scholar
• Creasman W. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstetr. 2009;105(2):109. doi:10.1016/j.ijgo.2009.02.010
   PubMed Web of Science ®Google Scholar
• Amant F, Mirza M, Koskas M, Creutzberg C. Cancer of the corpus uteri. Int J Gynaecol Obstetr. 2018;143:37–50. doi:10.1002/ijgo.12612
   PubMed Web of Science ®Google Scholar
• Geisler J, Linnemeier G, Manahan K. Pelvic and para-aortic lymphadenectomy in patients with endometrioid adenocarcinoma of the endometrium. Int J Gynaecol Obstetr. 2007;98(1):39–43. doi:10.1016/j.ijgo.2007.03.035
   PubMed Web of Science ®Google Scholar
• Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707–1716. doi:10.1093/jnci/djn397
   PubMedGoogle Scholar
• Todo Y, Sakuragi N. Methodological considerations in the analysis of the therapeutic significance of lymphadenectomy in endometrial cancer. Taiwan J Obstet Gynecol. 2013;52(1):8–13. doi:10.1016/j.tjog.2013.01.003
   PubMed Web of Science ®Google Scholar
• Cragun J, Havrilesky L, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol. 2005;23(16):3668–3675. doi:10.1200/JCO.2005.04.144
   PubMed Web of Science ®Google Scholar
• Ünsal M, Kimyon Comert G, Karalok A, et al. The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer. Ginekol Pol. 2018;89(11):599–606. doi:10.5603/GP.a2018.0103
   PubMedGoogle Scholar
• Yang B, Shan B, Xue X, et al. Predicting lymph node metastasis in endometrial cancer using serum CA125 combined with immunohistochemical markers PR and Ki67, and a comparison with other prediction models. PLoS One. 2016;11(5):e0155145. doi:10.1371/journal.pone.0155145
   PubMed Web of Science ®Google Scholar
• Kokot I, Piwowar A, Jędryka M, Sołkiewicz K, Kratz E. Diagnostic significance of selected serum inflammatory markers in women with advanced endometriosis. Int J Mol Sci. 2021;22(5):2295. doi:10.3390/ijms22052295
   PubMed Web of Science ®Google Scholar
• Qin C, Gao Y, Li J, Huang C, He S. Predictive effects of preoperative serum CA125 and AFP levels on post-hepatectomy survival in patients with hepatitis B-related hepatocellular carcinoma. Oncol Lett. 2021;21(6):487. doi:10.3892/ol.2021.12748
   PubMed Web of Science ®Google Scholar
• Liu J, Li S, Zhang S, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33(8):e22964. doi:10.1002/jcla.22964
   PubMed Web of Science ®Google Scholar
• Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep. 2019;9(1):3284. doi:10.1038/s41598-019-39150-0
   PubMed Web of Science ®Google Scholar
• Shui Y, Li M, Su J, Chen M, Gu X, Guo W. Prognostic and clinicopathological significance of systemic immune-inflammation index in pancreatic cancer: a meta-analysis of 2365 patients. Aging. 2021;13:20585–20597. doi:10.18632/aging.203449
   PubMedGoogle Scholar
• Deng Y, Zhao Y, Qin J, et al. Prognostic value of the C-reactive protein/albumin ratio and systemic immune-inflammation index for patients with colorectal liver metastasis undergoing curative resection. Pathol Oncol Res. 2021;27:633480. doi:10.3389/pore.2021.633480
   PubMed Web of Science ®Google Scholar
• Matsubara S, Mabuchi S, Takeda Y, Kawahara N, Kobayashi H. Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer. PLoS One. 2021;16(5):e0248871. doi:10.1371/journal.pone.0248871
   PubMed Web of Science ®Google Scholar
• Holub K, Busato F, Gouy S, et al. Analysis of systemic inflammatory factors and survival outcomes in endometrial cancer patients staged I-III FIGO and treated with postoperative external radiotherapy. J Clin Med. 2020;9(5):1441. doi:10.3390/jcm9051441
   PubMed Web of Science ®Google Scholar
• Diakos C, Charles K, McMillan D, Clarke S. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Crusz S, Balkwill F. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–596. doi:10.1038/nrclinonc.2015.105
   PubMed Web of Science ®Google Scholar
• Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer. 2013;13(12):842–857. doi:10.1038/nrc3613
   PubMed Web of Science ®Google Scholar
• Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28(26):4045–4051. doi:10.1200/JCO.2010.27.9992
   PubMed Web of Science ®Google Scholar
• Burgess B, Levine B, Taylor R, Kelly M. Preoperative circulating lymphocyte and monocyte counts correlate with patient outcomes in type I and type II endometrial cancer. Reprod Sci. 2020;27(1):194–203. doi:10.1007/s43032-019-00009-4
   PubMed Web of Science ®Google Scholar
• Aoyama T, Takano M, Miyamoto M, et al. Pretreatment neutrophil-to-lymphocyte ratio was a predictor of lymph node metastasis in endometrial cancer patients. Oncology. 2019;96(5):259–267. doi:10.1159/000497184
   PubMed Web of Science ®Google Scholar
• Moses K, Brandau S. Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells. Semin Immunol. 2016;28(2):187–196. doi:10.1016/j.smim.2016.03.018
   PubMed Web of Science ®Google Scholar
• Yokoi E, Mabuchi S, Komura N, et al. The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations. Oncoimmunology. 2019;8(12):e1662708. doi:10.1080/2162402X.2019.1662708
   PubMed Web of Science ®Google Scholar
• Chen H, Wu Q, Zhang Y, et al. Nomograms based on the novel platelet index score predict postoperative prognosis in endometrial cancer. Gynecol Oncol. 2020;158(3):689–697. doi:10.1016/j.ygyno.2020.05.040
   PubMed Web of Science ®Google Scholar
• Mahdi H, Jernigan A, Nutter B, Michener C, Rose P. Lymph node metastasis and pattern of recurrence in clinically early stage endometrial cancer with positive lymphovascular space invasion. J Gynecol Oncol. 2015;26(3):208–213. doi:10.3802/jgo.2015.26.3.208
   PubMed Web of Science ®Google Scholar
• Hahn H, Lee I, Kim T, et al. Lymphovascular space invasion is highly associated with lymph node metastasis and recurrence in endometrial cancer. Aust N Z J Obstet Gynaecol. 2013;53(3):293–297. doi:10.1111/ajo.12089
   PubMed Web of Science ®Google Scholar
• Jiang P, Huang Y, Tu Y, et al. Combining clinicopathological parameters and molecular indicators to predict lymph node metastasis in endometrioid type endometrial adenocarcinoma. Front Oncol. 2021;11:682925. doi:10.3389/fonc.2021.682925
   PubMed Web of Science ®Google Scholar
• Nithin K, Sridhar M, Srilatha K, Habebullah S. CA 125 is a better marker to differentiate endometrial cancer and abnormal uterine bleeding. Afr Health Sci. 2018;18(4):972–978. doi:10.4314/ahs.v18i4.17
   PubMed Web of Science ®Google Scholar
• Li X, Xu Y, Zhang L. Serum CA153 as biomarker for cancer and noncancer diseases. Prog Mol Biol Transl Sci. 2019;162:265–276.
   PubMed Web of Science ®Google Scholar